Abstract:

Objective To evaluate the efficacy and safety of glucagon like peptide-1(GLP-1) receptor agonist and metformin for the treatment of polycystic ovary syndrome (PCOS). Methods Two researchers searched the databases including PubMed, CENTRAL (Issue 3, 2020), EMbase, Wanfang Data, CBM, CNKI to collect the randomized controlled trails (RCTs) about GLP-1 receptor agonist for polycystic ovary syndrome, the retrieval time limit was defined as from the establishment of the database until April 2020. The two researchers screened the literature, extracted data, and evaluated the risk of bias in the included research data, and used RevMan 5.3 software to conduct a meta-analysis. Results A total of 10 RCTs (5 RCTs with exenatide and 5 RCTs with liraglutide) involving 654 patients were included. In terms of efficacy, body mass index (BMI), abdominal circumference, homeostasis model assessment of insulin resistance (HOMA-IR) in GLP-1 group were significantly lower than those in metformin group. In safety, the incidence of nausea and headache in GLP-1 group was significantly higher than those in metformin group. The incidence of diarrhea in GLP-1 group was significantly lower than that in metformin group. Conclusion GLP-1 receptor agonists were significantly better than metformin in reducing BMI, abdominal circumference, HOMA-IR in PCOS patients. However, the medicines are more likely to cause adverse reactions such as nausea and headache.

Key words: polycystic ovary syndrome, glucagon like peptide-1 receptor agonist, metformin, meta-analysis